ArticleBone marrow research2011
Antibody-based therapies in multiple myeloma.
Article in Bone marrow research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Progress of immune senescence in multiple myeloma treatment resistance.Discover oncology · 2025Review
- Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma.International journal of molecular sciences · 2023Review
- Boosting Immunity against Multiple Myeloma.Cancers · 2021Review
- Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.Drug design, development and therapy · 2021Review
- Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma.Biomedicines · 2020Review
- Immunotherapeutic and Targeted Approaches in Multiple Myeloma.ImmunoTargets and therapy · 2020Review
- B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.Expert opinion on biological therapy · 2019Review
- Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development.Antibodies (Basel, Switzerland) · 2019Review
- Preclinical Development of CD38-Targeted [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Article
- Novel Immunotherapies for Multiple Myeloma.Current hematologic malignancy reports · 2017Review
- Article
- Should minimal residual disease negativity be the end point of myeloma therapy?Blood advances · 2017Article
- Progress and Paradigms in Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Development of Novel Immunotherapies for Multiple Myeloma.International journal of molecular sciences · 2016Review
- Role of interleukin-6 in cancer progression and therapeutic resistance.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.Oncotarget · 2016Article
- Article
- Article
- Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma.Molecular oncology · 2015Article
- GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.Haematologica · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unmet need for improved multiple myeloma (MM) therapy has stimulated clinical development of monoclonal antibodies (mAbs) targeting either MM cells or cells of the bone marrow (BM) microenvironment. In contrast to small-molecule inhibitors, therapeutic mAbs present the potential to specifically target tumor cells and directly induce an immune response to lyse tumor cells. Unique immune-effector mechanisms are only triggered by therapeutic mAbs but not by small molecule targeting agents. Although therapeutic murine mAbs or chimeric mAbs can cause immunogenicity, the advancement of genetic recombination for humanizing rodent mAbs has allowed large-scale production and designation of mAbs with better affinities, efficient selection, decreasing immunogenicity, and improved effector functions. These advancements of antibody engineering technologies have largely overcome the critical obstacle of antibody immunogenicity and enabled the development and subsequent Food and Drug Administration (FDA) approval of therapeutic Abs for cancer and other diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.